US20110293549A1 - Composition, method and kit for enhancing hair - Google Patents
Composition, method and kit for enhancing hair Download PDFInfo
- Publication number
- US20110293549A1 US20110293549A1 US12/698,823 US69882310A US2011293549A1 US 20110293549 A1 US20110293549 A1 US 20110293549A1 US 69882310 A US69882310 A US 69882310A US 2011293549 A1 US2011293549 A1 US 2011293549A1
- Authority
- US
- United States
- Prior art keywords
- composition
- compound
- group
- hair
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 0 *C(B)(cc-c1c(CccCC(=O)N(C)C)C([1*])cc-1[2*])CCC Chemical compound *C(B)(cc-c1c(CccCC(=O)N(C)C)C([1*])cc-1[2*])CCC 0.000 description 13
- UKWTUVPJZHQATR-YCASNBFMSA-N COC(=O)CCC/C=C\C[C@H]1C(O)CC(O)[C@@H]1/C=C/C(F)(F)COC1=CC=CC=C1 Chemical compound COC(=O)CCC/C=C\C[C@H]1C(O)CC(O)[C@@H]1/C=C/C(F)(F)COC1=CC=CC=C1 UKWTUVPJZHQATR-YCASNBFMSA-N 0.000 description 2
- VJZKLIPANASSBD-ZQCOTFBWSA-N CCNC(=O)CCC/C=C\C[C@H]1C(O)CC(O)[C@@H]1/C=C/C(F)(F)COC1=CC=CC=C1 Chemical compound CCNC(=O)CCC/C=C\C[C@H]1C(O)CC(O)[C@@H]1/C=C/C(F)(F)COC1=CC=CC=C1 VJZKLIPANASSBD-ZQCOTFBWSA-N 0.000 description 1
- KIQXRQVVYTYYAZ-GGXXSZQPSA-N O=C(O)CCC/C=C\C[C@H]1C(O)CC(O)[C@@H]1/C=C/C(F)(F)COC1=CC=CC=C1 Chemical compound O=C(O)CCC/C=C\C[C@H]1C(O)CC(O)[C@@H]1/C=C/C(F)(F)COC1=CC=CC=C1 KIQXRQVVYTYYAZ-GGXXSZQPSA-N 0.000 description 1
- SVXRVUBLDKOURB-WYUCAYHJSA-N [H]N(C)C(=O)CCC/C=C/C[C@@H](CO)[C@@H](/C=C/C(F)(F)COC1=CC=CC=C1)CO.[H]N(C)C(=O)CCC/C=C/C[C@H]1C(O)CC(O)[C@@H]1/C=C/C(F)(F)CCC1=CC=CC=C1.[H]N(C)C(=O)CCC/C=C/C[C@H]1C(O)CC(O)[C@@H]1/C=C/C(F)(F)COC1=CC=CC=C1.[H]N(CC)C(=O)CCC/C=C/C[C@H]1C(O)CC(O)[C@@H]1/C=C/C(F)(F)CCC1=CC=CC(C(F)(F)F)=C1.[H]N(CC)C(=O)CCC/C=C/C[C@H]1C(O)CC(O)[C@@H]1/C=C/C(F)(F)CCC1=CC=CC=C1 Chemical compound [H]N(C)C(=O)CCC/C=C/C[C@@H](CO)[C@@H](/C=C/C(F)(F)COC1=CC=CC=C1)CO.[H]N(C)C(=O)CCC/C=C/C[C@H]1C(O)CC(O)[C@@H]1/C=C/C(F)(F)CCC1=CC=CC=C1.[H]N(C)C(=O)CCC/C=C/C[C@H]1C(O)CC(O)[C@@H]1/C=C/C(F)(F)COC1=CC=CC=C1.[H]N(CC)C(=O)CCC/C=C/C[C@H]1C(O)CC(O)[C@@H]1/C=C/C(F)(F)CCC1=CC=CC(C(F)(F)F)=C1.[H]N(CC)C(=O)CCC/C=C/C[C@H]1C(O)CC(O)[C@@H]1/C=C/C(F)(F)CCC1=CC=CC=C1 SVXRVUBLDKOURB-WYUCAYHJSA-N 0.000 description 1
- DRFFAAFZMTXKIP-YEHIAZMESA-N [H]N(C)C(=O)CCC/C=C/C[C@H]1C(O)CC(O)[C@@H]1/C=C/C(F)(F)CCC1=CC=CC=C1 Chemical compound [H]N(C)C(=O)CCC/C=C/C[C@H]1C(O)CC(O)[C@@H]1/C=C/C(F)(F)CCC1=CC=CC=C1 DRFFAAFZMTXKIP-YEHIAZMESA-N 0.000 description 1
- SFFUDLTWBDEYHI-BDLKZJKZSA-N [H]N(C)C(=O)CCC/C=C/C[C@H]1C(O)CC(O)[C@@H]1/C=C/C(F)(F)CCC1=CC=CC=C1.[H]N(C)C(=O)CCC/C=C/C[C@H]1C(O)CC(O)[C@@H]1/C=C/C(F)(F)COC1=CC=CC=C1.[H]N(CC)C(=O)CCC/C=C/C[C@H]1C(O)CC(O)[C@@H]1/C=C/C(F)(F)CCC1=CC=CC(C(F)(F)F)=C1.[H]N(CC)C(=O)CCC/C=C/C[C@H]1C(O)CC(O)[C@@H]1/C=C/C(F)(F)CCC1=CC=CC=C1.[H]N(CC)C(=O)CCC/C=C/C[C@H]1C(O)CC(O)[C@@H]1/C=C/C(F)(F)COC1=CC=CC=C1 Chemical compound [H]N(C)C(=O)CCC/C=C/C[C@H]1C(O)CC(O)[C@@H]1/C=C/C(F)(F)CCC1=CC=CC=C1.[H]N(C)C(=O)CCC/C=C/C[C@H]1C(O)CC(O)[C@@H]1/C=C/C(F)(F)COC1=CC=CC=C1.[H]N(CC)C(=O)CCC/C=C/C[C@H]1C(O)CC(O)[C@@H]1/C=C/C(F)(F)CCC1=CC=CC(C(F)(F)F)=C1.[H]N(CC)C(=O)CCC/C=C/C[C@H]1C(O)CC(O)[C@@H]1/C=C/C(F)(F)CCC1=CC=CC=C1.[H]N(CC)C(=O)CCC/C=C/C[C@H]1C(O)CC(O)[C@@H]1/C=C/C(F)(F)COC1=CC=CC=C1 SFFUDLTWBDEYHI-BDLKZJKZSA-N 0.000 description 1
- IVLOTYOZHGQVAN-WKZUIPNOSA-N [H]N(C)C(=O)CCC/C=C/C[C@H]1C(O)CC(O)[C@@H]1/C=C/C(F)(F)COC1=CC=CC=C1 Chemical compound [H]N(C)C(=O)CCC/C=C/C[C@H]1C(O)CC(O)[C@@H]1/C=C/C(F)(F)COC1=CC=CC=C1 IVLOTYOZHGQVAN-WKZUIPNOSA-N 0.000 description 1
- DRFFAAFZMTXKIP-ANKXTQHUSA-N [H]N(C)C(=O)CCC/C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1/C=C/C(F)(F)CCC1=CC=CC=C1 Chemical compound [H]N(C)C(=O)CCC/C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1/C=C/C(F)(F)CCC1=CC=CC=C1 DRFFAAFZMTXKIP-ANKXTQHUSA-N 0.000 description 1
- IVLOTYOZHGQVAN-WIJTVMHTSA-N [H]N(C)C(=O)CCC/C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1/C=C/C(F)(F)COC1=CC=CC=C1 Chemical compound [H]N(C)C(=O)CCC/C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1/C=C/C(F)(F)COC1=CC=CC=C1 IVLOTYOZHGQVAN-WIJTVMHTSA-N 0.000 description 1
- FYWRPXYGGVVRTJ-CHECXLDVSA-N [H]N(C)C(=O)CCC/C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1/C=C/[C@@H](O)CCC1=CC(C(F)(F)F)=CC=C1.[H]N(C)C(=O)CCC/C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1/C=C/[C@@H](O)CCC1=CC(C(F)(F)F)=CC=C1.[H]N(C)C(=O)CCC/C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1/C=C/[C@@H](O)COC1=CC(C(F)(F)F)=CC=C1.[H]N(CC)C(=O)CCC/C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1/C=C/[C@@H](O)COC1=CC(C(F)(F)F)=CC=C1 Chemical compound [H]N(C)C(=O)CCC/C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1/C=C/[C@@H](O)CCC1=CC(C(F)(F)F)=CC=C1.[H]N(C)C(=O)CCC/C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1/C=C/[C@@H](O)CCC1=CC(C(F)(F)F)=CC=C1.[H]N(C)C(=O)CCC/C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1/C=C/[C@@H](O)COC1=CC(C(F)(F)F)=CC=C1.[H]N(CC)C(=O)CCC/C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1/C=C/[C@@H](O)COC1=CC(C(F)(F)F)=CC=C1 FYWRPXYGGVVRTJ-CHECXLDVSA-N 0.000 description 1
- YXFDHJVQVJMAKW-GQOWFAAMSA-N [H]N(C)C(=O)CCC/C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1/C=C/[C@@H](O)COC1=CC(C(F)(F)F)=CC=C1 Chemical compound [H]N(C)C(=O)CCC/C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1/C=C/[C@@H](O)COC1=CC(C(F)(F)F)=CC=C1 YXFDHJVQVJMAKW-GQOWFAAMSA-N 0.000 description 1
- VGXZJUHBFKABLQ-CXWPCLHSSA-N [H]N(CC)C(=O)CCC/C=C/C[C@H]1C(O)CC(O)[C@@H]1/C=C/C(F)(F)CCC1=CC=CC=C1 Chemical compound [H]N(CC)C(=O)CCC/C=C/C[C@H]1C(O)CC(O)[C@@H]1/C=C/C(F)(F)CCC1=CC=CC=C1 VGXZJUHBFKABLQ-CXWPCLHSSA-N 0.000 description 1
- VJZKLIPANASSBD-CEXCVAEWSA-N [H]N(CC)C(=O)CCC/C=C/C[C@H]1C(O)CC(O)[C@@H]1/C=C/C(F)(F)COC1=CC=CC=C1 Chemical compound [H]N(CC)C(=O)CCC/C=C/C[C@H]1C(O)CC(O)[C@@H]1/C=C/C(F)(F)COC1=CC=CC=C1 VJZKLIPANASSBD-CEXCVAEWSA-N 0.000 description 1
- VGXZJUHBFKABLQ-ISGIBKLWSA-N [H]N(CC)C(=O)CCC/C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1/C=C/C(F)(F)CCC1=CC=CC=C1 Chemical compound [H]N(CC)C(=O)CCC/C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1/C=C/C(F)(F)CCC1=CC=CC=C1 VGXZJUHBFKABLQ-ISGIBKLWSA-N 0.000 description 1
- VJZKLIPANASSBD-VIGZLNKHSA-N [H]N(CC)C(=O)CCC/C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1/C=C/C(F)(F)COC1=CC=CC=C1 Chemical compound [H]N(CC)C(=O)CCC/C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1/C=C/C(F)(F)COC1=CC=CC=C1 VJZKLIPANASSBD-VIGZLNKHSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/42—Amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/69—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing fluorine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q7/00—Preparations for affecting hair growth
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/32—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
- C07C235/34—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
- C07C405/0008—Analogues having the carboxyl group in the side-chains replaced by other functional groups
- C07C405/0041—Analogues having the carboxyl group in the side-chains replaced by other functional groups containing nitrogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/88—Two- or multipart kits
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
- C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/13—Hollow or container type article [e.g., tube, vase, etc.]
Definitions
- composition Composition, method and kit for enhancing human hair including eyelashes.
- Minoxidil 6-(1-piperidinyl)-2,4-pyrimidane-diamine-3-oxide
- Minoxidil was originally prepared and sold for use as an antihypertensive. It was observed that, associated with the use of Minoxidil for this latter purpose, Minoxidil use also produced an increase in hair growth and thickness as reported in U.S. Pat. Nos. 4,139,619 and 4,968,812.
- Today, Minoxidil is marketed under the trademark Rogaine® by Pfizer for the treatment of baldness on the scalp for men (alopecia androgenetica) and women.
- finasteride Propecia®
- Merck & Co Another example is finasteride (Propecia®), marketed by Merck & Co. Finasteride was originally developed for benign prostatic hypertrophy, and was found to be effective in the treatment of alopecia androgenetica as reported in U.S. Pat. No. 4,968,812.
- Latanoprost is marketed by Pharmacia & Upjohn (currently a part of Pfizer) under the trademark Xalatan® for the reduction of elevated intraocular pressure in patients with glaucoma and ocular hypertension.
- the form is a Latanoprost optical solution of 0.005% (50 ⁇ g/ml), and is applied by dropper directly onto the eye. One drop generally contains approximately 1.5 ⁇ g of Latanoprost.
- Latanoprost has been reported to cause, in some patients, an increasing pigmentation and growth of eyelashes.
- U.S. Pat. No. 6,262,105 stated that the use of Latanoprost leads to increased length of lashes, increased numbers of lashes along the normal lash line, increased thickness and luster of lashes, increased auxiliary lash-like terminal hair in transitional areas adjacent to areas of normal lash growth, increased lash-like terminal hairs at the medial and lateral canthal area, increased pigmentation of the lashes, increased numbers, increased length, as well as increased luster, and thickness of fine hair on the skin of the adjacent lid, and increased perpendicular angulation of lashes and lash-like terminal hairs.
- Alcon, Inc. (“Alcon”) introduced a prostaglandin F2 ⁇ analog, commonly known as Travoprost whose chemical name is isopropyl (z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(1E,3R)-3-hydroxy-4-[( ⁇ , ⁇ , ⁇ -trifluoro-m-tolyl)oxyl]-1-butenyl]cyclopentyl]-5-heptenoate as a glaucoma treatment. Alcon also sought patent protection for Travoprost for growing hair in U.S. Patent Application No. 2003/0199590.
- Allergan, Inc. (“Allergan”) introduced Bimatoprost whose chemical name is cyclopentane N-ethyl haptanamide-5-cis-2-(3 ⁇ -hydrosy-5-phenyl-1-trans-pentenyl)-3,5-dihydroxy,[1 ⁇ , 2 ⁇ , 3 ⁇ , 5 ⁇ ) for treating glaucoma.
- U.S. Pat. No. 7,351,404 is directed at the use of this molecule and similar molecules for growing hair, including eyelashes. Allergan distinguishes the Bimatoprost molecule from other prostaglandins on the basis that Bimatoprost is a prostamide.
- U.S. Pat. Nos. 5,886,035 and 5,985,920 describe fluorine containing prostaglandin derivatives for use as a preventive or therapeutic medicine for an eye disease such as glaucoma or elevated intraocular pressure.
- FIG. 1 shows a process flow from a Corey acetate derivative to a difluoro compound that includes an ethyl amide.
- Enhancing hair as used herein includes stimulating or promoting growth of existing hair, including stimulating or promoting a bulb or cells in a follicle associated with the formation of an actual hair into hair growth. Hair growth in this sense includes an increase in length and/or an increase in diameter of a hair. Enhancing hair also includes conditioning hair and/or cosmetically improving the appearance or beauty of the hair such that hair subject to the compound or a composition including the compound appears or feels longer, thicker and fuller. Enhancing hair also includes darkening the hair. The location of the hair includes the scalp (e.g., scalp hair), eyelid (e.g., eyelashes), and brow (e.g., eyebrows) and any other portion of human skin where hair exists or may be desired.
- scalp hair e.g., scalp hair
- eyelid e.g., eyelashes
- brow e.g., eyebrows
- a composition includes an effective hair enhancing amount of a compound represented by the following formula:
- R and R′ are individually selected from hydrogen, or a C 1 -C 6 straight or branched chain alkyl (e.g., methyl, ethyl, isopropyl);
- the molecule may be characterized as a difluoro prostaglandin or prostaglandin-like compound because its backbone resembles a prostaglandin.
- a difluoro compound may be in a molecular free form (a molecule) or an acceptable salt thereof (a compound).
- An acceptable salt is a dermatologically acceptable salt or a pharmaceutically acceptable salt.
- An example of a salt is a hydrohalide salt of the molecule such as a hydrochloride salt.
- the resulting salt compound will have the proton from the hydrohalide bonded to the nitrogen of the molecule and be charge balanced by the halide.
- the compound has the following formula:
- R, R′, X, y and x are defined above, or an acceptable salt thereof.
- the compound is one of the following molecules or a salt thereof:
- one or more compounds described above is/are mixed with a dermatologically compatible vehicle or carrier to form a composition.
- Suitable vehicles include, for example, aqueous solutions such as e.g., physiological salines, oil (e.g., castor oil), solutions, foams, creams or ointments.
- Suitable vehicles furthermore may contain dermatologically compatible preservatives such as e.g., benzalkonium chloride, surfactants like e.g., polysorbate 80, liposomes or polymers, for example, methyl cellulose, polyvinyl alcohol, polyvinyl pyrrolidone and hyaluronic acid; these may be used for increasing the viscosity.
- dermatological compositions for topical treatment for enhancing hair that include an effective hair enhancing amount of one or more compounds as defined above and a dermatologically compatible carrier are also disclosed.
- Effective amounts of the active compounds may be determined by one of ordinary skill in the art but will vary depending on the compound employed, frequency of application and desired result.
- An amount of a compound or compounds will generally range from about 0.0000001 to about 10 percent, by weight, of the dermatological composition, preferably from about 0.0001 to about 10 percent, by weight, of total dermatological composition.
- a composition may include a combination of difluoro prostaglandin or prostaglandin-like compounds described or a compound(s) and other hair treatment aids such as an antioxidant (e.g., Vitamin E), a vasodilator (e.g., minoxidil), an antimicrobial (e.g., benzoyl peroxide), or an anti-inflammatory (e.g., hydrocortisone, cyclooxygenase inhibitor, lipooxigenase inhibitor).
- an antioxidant e.g., Vitamin E
- a vasodilator e.g., minoxidil
- an antimicrobial e.g., benzoyl peroxide
- an anti-inflammatory e.g., hydrocortisone, cyclooxygenase inhibitor, lipooxigenase inhibitor.
- the composition may be topically applied to the dermis of, for example, a human in an area desired for enhancing hair such as direct application to existing hair or the dermis in an area desired for hair enhancing as opposed to an indirect application such as to the surface of the eye.
- a human in an area desired for enhancing hair
- Such location may include the scalp, eyelash area or eyelid or brow of a male or female.
- Application of the compound(s) or composition to a base of a hair or hairs may create a wicking action where the compound(s) are drawn up the length of the hair or hairs.
- Repeated application for a sustained period of time e.g., daily for several weeks or more (e.g., one month to several months) may be desired.
- the composition may be applied directly to the dermis where hair growth is desired.
- This may include the scalp where, for example, a density of existing hair has been reduced due to alopecia or other mechanism (e.g., hair loss as a side effect to chemotherapy treatment).
- alopecia or other mechanism e.g., hair loss as a side effect to chemotherapy treatment.
- an absence of pubic hair is considered bad luck and can be a serious problem, particularly in women.
- the composition may be applied to the pubic area to address this problem.
- repeated daily topical application of a composition to an area of the dermis where hair growth is desired may continue until hair growth is effected and may continue periodically (daily, weekly) to maintain such growth.
- such topical application to the dermis may, for example, utilize a delivery vehicle including the composition that is a foam or cream.
- a composition including at least one difluoro prostaglandin or prostaglandin-like compound as described above may be applied at the base of an eyelid adjacent to or where hair grows from the follicles (e.g., along the lash line).
- the composition may be applied to the eyelashes themselves. Repeated application for consecutive days, weeks or months (e.g., regular daily application for six months) of the composition to eyelashes or areas of eyelid dermis associated with eyelashes (e.g., the base of an eyelid containing follicles in which eyelashes grow) will condition and cosmetically enhance existing eyelashes such that the eyelashes appear longer, thicker and fuller. Such application will also stimulate or promote the growth of eyelashes.
- a kit in another embodiment, may include the composition of at least one difluoro prostaglandin or prostaglandin-like compound as described above in a dermatologically compatible vehicle or carrier in a container.
- the container includes an amount of the composition for repeated application over a period, such as enough of the composition for daily application over a period of six months.
- the container may also include an applicator, such as a mascara brush or other instrument for application of the composition to skin.
- the container may be pressurized and include a nozzle to dispense a desired amount onto the hand of a user.
- an omega chain backbone such as dimethyl 2-oxo-3-phenoxy-propyl phosphonate is added via an exchange reaction.
- the oxo group in the 2 position is preserved in the formed intermediate and then reduced with a fluorine compound to produce a difluoro precursor.
- the alpha chain is added at another site of the Corey acetate derivative yielding 3,3-difluoro-4-phenoxybut-1-enyl-3,5-dihydroxycyclopentyl-hept-5-enoic acid.
- FIG. 1 shows a process flow from a Corey acetate derivative to the acid, to the ester and then to an ethyl amide (Compound 3).
- U.S. Pat. No. 5,886,035 also describes a method of preparing difluoro-prostaglandin derivatives but does not describe the use of such derivatives in hair (eyelash) growth.
- compositions for topical application and methods of topical application of a composition to modify hair are described wherein the modification includes increased curl of hair on a subject or hair that is not biologically attached to or is not naturally a part of a subject (e.g., hair of a wig or extension) (“non-natural hair”).
- the modification includes increased curl of the hair together with conditioning hair and/or cosmetically improving the appearance or beauty of the hair (e.g., increased look and feel of softness and silkiness).
- the compositions described may be applied to existing hair on the scalp or eyelashes or non-natural hair to increase the curl and/or the look and feel of the hair.
- a composition includes an effective amount of a compound represented by the following formula:
- dashed bonds represent a single or double bond and when a bond in either chain is a double bond, cis or trans configuration is contemplated;
- a and B are individually selected from a hydrogen atom, a hydroxyl group (—OH) and a halogen atom (e.g., a fluorine atom), with the proviso that when one of A and B is a hydroxyl group, the other of A and B is a hydrogen atom and when one of A and B is a halogen atom, the other of A and B is a halogen atom or a hydrogen atom;
- Z is a cycloalkyl moiety having from three to seven carbon atoms, an aryl moiety including from four to ten carbon atoms or a heteroaryl moiety including three to nine carbon atoms and at least one heteroatom selected from nitrogen, oxygen and sulfur; and
- X 1 and X 2 are individually selected from a hydrogen atom, an alkyl moiety having from one to six carbon atoms,
- R 5 is an alkyl moiety having from one to six carbon atoms
- R 1 and R 2 are individually selected from an oxo group ( ⁇ O), a hydroxyl group (—OH) or an ester group (—O(CO)R 6 ), and R 6 is a saturated or unsaturated acyclic hydrocarbon group having from 1 to about 20 carbon atoms, and —(CH 2 ) m R 7 wherein m is 0 or an integer of from 1 to 10, and R 7 is cycloalkyl group, having from three to seven carbon atoms, or an aryl or heteroaryl group, as defined above;
- the compound may be in free form (a molecule) or an acceptable salt thereof (a compound) such as a cationic or anionic salt formed at the nitrogen atom of the molecule, in association with a carrier adapted for topical application to mammalian skin.
- a compound such as a cationic or anionic salt formed at the nitrogen atom of the molecule, in association with a carrier adapted for topical application to mammalian skin.
- reference to a compound will include a molecule or a compound.
- the compound is represented by the following formula:
- Y is selected from an alkyl group, a halogen atom (e.g., fluorine, chlorine), a nitro group, an amino group, a thiol group, a hydroxy group, an alkyloxy group, an alkylcarboxy group, a halo substituted alkyl wherein the alkyl includes from one to six carbon atoms, and n is 0 or an integer of from 1 to 3, or an acceptable salt thereof.
- a halogen atom e.g., fluorine, chlorine
- the compound has the following formula:
- A, B, X 1 , X 2 , Y and n are as defined above, or an acceptable salt thereof.
- the compound is selected from any of compounds (1)-(5) above or a molecule having one of the following formulas or a salt thereof:
- Compounds (6)-(9) may be prepared using techniques known in the art including, for example, techniques described in U.S. Pat. Nos. 5,001,153; 5,422,368; 5,510,383; and 5,607,978.
- the one or more compounds described above is/are mixed with a dermatologically compatible vehicle or carrier.
- Suitable vehicles include, for example, aqueous solutions such as e.g., physiological salines, oil (e.g., castor oil), water solutions, water/alcohol solutions or ointments.
- Suitable vehicles furthermore may contain dermatologically compatible preservatives such as e.g., benzalkonium chloride, surfactants like e.g., polysorbate 80, liposomes or polymers, for example, methyl cellulose, polyvinyl alcohol, polyvinyl pyrrolidone and hyaluronic acid; these may be used for increasing the viscosity.
- dermatological compositions for topical treatment for inducing or stimulating modification of existing hair including increased curl which include an effective hair modifying amount of one or more compounds as defined above and a dermatologically compatible carrier are also disclosed wherein the modification includes increased curl of hair or increased curl.
- Effective amounts of the compound may be determined by one of ordinary skill in the art but will vary depending on the compound employed, frequency of application and desired result, and the compound will generally range from about 0.0000001 to about 50%, by weight, of the dermatological composition, preferably from about 0.001 to about 50%, by weight, of total dermatological composition, more preferably from about 0.1 to about 30%, by weight of the composition.
- a composition may include a combination of compounds described or a compound(s) and other hair treatment aids such as an antioxidant (e.g., Vitamin E), a vasodilator (e.g., minoxidil), an antimicrobial (e.g., benzoyl peroxide), or an anti-inflammatory (e.g., hydrocortisone, cyclooxygenase inhibitor, lipooxigenase inhibitor).
- an antioxidant e.g., Vitamin E
- a vasodilator e.g., minoxidil
- an antimicrobial e.g., benzoyl peroxide
- an anti-inflammatory e.g., hydrocortisone, cyclooxygenase inhibitor, lipooxigenase inhibitor.
- the composition may be topically applied to existing hair and retained on the hair. Such location may include the scalp or eyelash area of a male or female. Repeated application for a sustained period of time (e.g., daily for several weeks or more (e.g., one month to several months)) may be desired.
- the composition may be beneficial to persons that naturally have straight scalp hair to aid in the curl of such hair.
- Evidence of the effectiveness of a composition of compound (3) (dechloro-dihydroxy-difluoro-ethylcloprostenate) and, alternatively, of compound (8) (trifluoromethyl dechloroethyl prostenolamide) in application to generally straight Asian hair indicates a profound curling effect.
- the composition is suitable for modifying eyelashes.
- a composition would be provided to a subject with instructions on use (e.g., by instructions on or with a kit, the kit including the composition and the instructions). The subject would be instructed to apply the composition to eyelash hair.
- modifying the eyelashes e.g., increasing the curl and/or look and feel
- it is anticipated that application to a hair follicle will increase the thickness (e.g., diameter) of the follicle.
- the composition may be topically applied to hair on the scalp.
- a subject interested in establishing a curl to a portion of the subject's scalp hair or improving a natural curl would be instructed (e.g., by instructions on or with a kit) to topically apply the composition to the desired portion of the hair and to leave the composition on the hair.
- a period of time e.g., days, weeks
- the subject would be instructed to repeat the application for a period ranging from days to weeks.
- the applications described above may be used to modify non-natural hair (e.g., hair not biologically attached to or is not naturally a part of a subject).
- non-natural hair e.g., hair not biologically attached to or is not naturally a part of a subject.
- hair include, but are not limited to, wigs and hair extensions.
- a kit in another embodiment, may include the composition of at least one compound having the formula III or IV as described above in a dermatologically compatible vehicle or carrier in a container.
- the container includes an amount of the composition for repeated application over a period, such as enough of the composition for daily application over a period of six months.
- the container may also include an applicator, such as a mascara brush or other instrument for application of the composition to skin.
- an applicator such as a mascara brush or other instrument for application of the composition to skin.
- the container may be pressurized and include a nozzle to dispense a desired amount onto the hand of a user.
- TDP trifluoromethyl dechloroethyl prostenolamide
- a solution of TDP was prepared including 97.6 percent water, 0.24 percent TDP and 2.16 percent ethyl alcohol.
- Samples of human hair separated from a subject were treated with water alone while others were treated with the TDP solution.
- the treatment involved dipping the dry hair samples into the water and TDP solutions to one minute.
- the hair treated with water alone did not show similar curl.
- the results are illustrated in FIG. 1 .
- the hair treated with the TDP solution had a noticeable and palpable increase in the look and feel of softness and silkiness compared to the hair treated with the water alone.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cosmetics (AREA)
Abstract
Compositions for application and methods of application of a composition to modify hair. In one embodiment, a composition includes a compound (molecule) represented by:
-
- wherein A and B are individually selected from a hydrogen, a hydroxyl group and a halogen, with the proviso that when one of A and B is a hydroxyl group, the other of A and B is a hydrogen and when one of A and B is a halogen, the other of A and B is a halogen or a hydrogen;
- wherein Z is, for example, an aryl moiety; and
- wherein X1 and X2 are, for example, individually selected from a hydrogen and an alkyl moiety,
- wherein R1 and R2 are individually selected from an oxo, a hydroxyl or an ester group;
- wherein y is 0 or 1, x is 0 or 1 and x and y are not both 1, or a salt.
Description
- The application claims the benefit of the earlier filing date of co-pending U.S. Provisional Patent Application No. 61/149,661, filed Feb. 3, 2009 and incorporated herein by reference.
- Composition, method and kit for enhancing human hair including eyelashes.
- Certain therapeutic agents have been known to induce hair growth. One example is Minoxidil, 6-(1-piperidinyl)-2,4-pyrimidane-diamine-3-oxide (U.S. Pat. Nos. 3,382,247 and 3,644,363). Minoxidil was originally prepared and sold for use as an antihypertensive. It was observed that, associated with the use of Minoxidil for this latter purpose, Minoxidil use also produced an increase in hair growth and thickness as reported in U.S. Pat. Nos. 4,139,619 and 4,968,812. Today, Minoxidil is marketed under the trademark Rogaine® by Pfizer for the treatment of baldness on the scalp for men (alopecia androgenetica) and women. Another example is finasteride (Propecia®), marketed by Merck & Co. Finasteride was originally developed for benign prostatic hypertrophy, and was found to be effective in the treatment of alopecia androgenetica as reported in U.S. Pat. No. 4,968,812.
- Among the drugs introduced for lowering intraocular pressure are molecules of the family prostaglandin F2. The Upjohn Company identified a prostaglandin F2α analog, commonly known as Latanoprost and whose chemical name is isopropyl-(Z)-7[(1R,2R,3R,5S)3,5-dihydroxy-2-[(3R)-3-hydroxy-5-phenyl p-entyl]cyclopentyl]-5-heptenoate. Latanoprost is marketed by Pharmacia & Upjohn (currently a part of Pfizer) under the trademark Xalatan® for the reduction of elevated intraocular pressure in patients with glaucoma and ocular hypertension. The form is a Latanoprost optical solution of 0.005% (50 μg/ml), and is applied by dropper directly onto the eye. One drop generally contains approximately 1.5 μg of Latanoprost.
- In the course of its use for reduction of intraocular pressure, Latanoprost has been reported to cause, in some patients, an increasing pigmentation and growth of eyelashes. U.S. Pat. No. 6,262,105 stated that the use of Latanoprost leads to increased length of lashes, increased numbers of lashes along the normal lash line, increased thickness and luster of lashes, increased auxiliary lash-like terminal hair in transitional areas adjacent to areas of normal lash growth, increased lash-like terminal hairs at the medial and lateral canthal area, increased pigmentation of the lashes, increased numbers, increased length, as well as increased luster, and thickness of fine hair on the skin of the adjacent lid, and increased perpendicular angulation of lashes and lash-like terminal hairs.
- Alcon, Inc. (“Alcon”) introduced a prostaglandin F2α analog, commonly known as Travoprost whose chemical name is isopropyl (z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(1E,3R)-3-hydroxy-4-[(α,α,α-trifluoro-m-tolyl)oxyl]-1-butenyl]cyclopentyl]-5-heptenoate as a glaucoma treatment. Alcon also sought patent protection for Travoprost for growing hair in U.S. Patent Application No. 2003/0199590.
- Allergan, Inc. (“Allergan”) introduced Bimatoprost whose chemical name is cyclopentane N-ethyl haptanamide-5-cis-2-(3α-hydrosy-5-phenyl-1-trans-pentenyl)-3,5-dihydroxy,[1α, 2α, 3α, 5α) for treating glaucoma. U.S. Pat. No. 7,351,404 is directed at the use of this molecule and similar molecules for growing hair, including eyelashes. Allergan distinguishes the Bimatoprost molecule from other prostaglandins on the basis that Bimatoprost is a prostamide.
- U.S. Pat. Nos. 5,886,035 and 5,985,920 describe fluorine containing prostaglandin derivatives for use as a preventive or therapeutic medicine for an eye disease such as glaucoma or elevated intraocular pressure.
-
FIG. 1 shows a process flow from a Corey acetate derivative to a difluoro compound that includes an ethyl amide. - Compositions for topical application, methods of topical application of a composition to enhance hair, and a kit are described. Enhancing hair as used herein includes stimulating or promoting growth of existing hair, including stimulating or promoting a bulb or cells in a follicle associated with the formation of an actual hair into hair growth. Hair growth in this sense includes an increase in length and/or an increase in diameter of a hair. Enhancing hair also includes conditioning hair and/or cosmetically improving the appearance or beauty of the hair such that hair subject to the compound or a composition including the compound appears or feels longer, thicker and fuller. Enhancing hair also includes darkening the hair. The location of the hair includes the scalp (e.g., scalp hair), eyelid (e.g., eyelashes), and brow (e.g., eyebrows) and any other portion of human skin where hair exists or may be desired.
- In one embodiment, a composition includes an effective hair enhancing amount of a compound represented by the following formula:
- wherein the dashed bonds represent a single or double bond that can be in the cis or trans configuration; R and R′ are individually selected from hydrogen, or a C1-C6 straight or branched chain alkyl (e.g., methyl, ethyl, isopropyl); X is a halide (e.g., F, Cl, Br, I) a halide-containing group (e.g., CF3), or hydrogen; either y=0 and x=1 or y=1 and x=0. The molecule may be characterized as a difluoro prostaglandin or prostaglandin-like compound because its backbone resembles a prostaglandin.
- A difluoro compound may be in a molecular free form (a molecule) or an acceptable salt thereof (a compound). An acceptable salt is a dermatologically acceptable salt or a pharmaceutically acceptable salt. An example of a salt is a hydrohalide salt of the molecule such as a hydrochloride salt. In one embodiment, the resulting salt compound will have the proton from the hydrohalide bonded to the nitrogen of the molecule and be charge balanced by the halide. Throughout this description, unless specifically indicated a reference to a compound includes a molecule or a compound.
- In another embodiment, the compound has the following formula:
- wherein R, R′, X, y and x are defined above, or an acceptable salt thereof.
- In a particular embodiment, the compound is one of the following molecules or a salt thereof:
- In one embodiment, one or more compounds described above is/are mixed with a dermatologically compatible vehicle or carrier to form a composition. Suitable vehicles include, for example, aqueous solutions such as e.g., physiological salines, oil (e.g., castor oil), solutions, foams, creams or ointments. Suitable vehicles furthermore may contain dermatologically compatible preservatives such as e.g., benzalkonium chloride, surfactants like e.g., polysorbate 80, liposomes or polymers, for example, methyl cellulose, polyvinyl alcohol, polyvinyl pyrrolidone and hyaluronic acid; these may be used for increasing the viscosity.
- In one embodiment, dermatological compositions for topical treatment for enhancing hair that include an effective hair enhancing amount of one or more compounds as defined above and a dermatologically compatible carrier are also disclosed. Effective amounts of the active compounds may be determined by one of ordinary skill in the art but will vary depending on the compound employed, frequency of application and desired result. An amount of a compound or compounds will generally range from about 0.0000001 to about 10 percent, by weight, of the dermatological composition, preferably from about 0.0001 to about 10 percent, by weight, of total dermatological composition.
- In another embodiment, a composition may include a combination of difluoro prostaglandin or prostaglandin-like compounds described or a compound(s) and other hair treatment aids such as an antioxidant (e.g., Vitamin E), a vasodilator (e.g., minoxidil), an antimicrobial (e.g., benzoyl peroxide), or an anti-inflammatory (e.g., hydrocortisone, cyclooxygenase inhibitor, lipooxigenase inhibitor).
- The composition may be topically applied to the dermis of, for example, a human in an area desired for enhancing hair such as direct application to existing hair or the dermis in an area desired for hair enhancing as opposed to an indirect application such as to the surface of the eye. Such location may include the scalp, eyelash area or eyelid or brow of a male or female. Application of the compound(s) or composition to a base of a hair or hairs may create a wicking action where the compound(s) are drawn up the length of the hair or hairs. Repeated application for a sustained period of time (e.g., daily for several weeks or more (e.g., one month to several months)) may be desired.
- Where hair is not present, the composition may be applied directly to the dermis where hair growth is desired. This may include the scalp where, for example, a density of existing hair has been reduced due to alopecia or other mechanism (e.g., hair loss as a side effect to chemotherapy treatment). In certain Asian cultures, an absence of pubic hair is considered bad luck and can be a serious problem, particularly in women. The composition may be applied to the pubic area to address this problem. In one embodiment, repeated daily topical application of a composition to an area of the dermis where hair growth is desired may continue until hair growth is effected and may continue periodically (daily, weekly) to maintain such growth. In one embodiment, such topical application to the dermis may, for example, utilize a delivery vehicle including the composition that is a foam or cream.
- To enhance eyelashes, a composition including at least one difluoro prostaglandin or prostaglandin-like compound as described above may be applied at the base of an eyelid adjacent to or where hair grows from the follicles (e.g., along the lash line). Alternatively or additionally, the composition may be applied to the eyelashes themselves. Repeated application for consecutive days, weeks or months (e.g., regular daily application for six months) of the composition to eyelashes or areas of eyelid dermis associated with eyelashes (e.g., the base of an eyelid containing follicles in which eyelashes grow) will condition and cosmetically enhance existing eyelashes such that the eyelashes appear longer, thicker and fuller. Such application will also stimulate or promote the growth of eyelashes.
- In another embodiment, a kit is disclosed. The kit may include the composition of at least one difluoro prostaglandin or prostaglandin-like compound as described above in a dermatologically compatible vehicle or carrier in a container. The container includes an amount of the composition for repeated application over a period, such as enough of the composition for daily application over a period of six months. The container may also include an applicator, such as a mascara brush or other instrument for application of the composition to skin. In the case of a composition in the form of a foam, the container may be pressurized and include a nozzle to dispense a desired amount onto the hand of a user.
- Starting from a Corey acetate derivative, an omega chain backbone, such as dimethyl 2-oxo-3-phenoxy-propyl phosphonate is added via an exchange reaction. The oxo group in the 2 position is preserved in the formed intermediate and then reduced with a fluorine compound to produce a difluoro precursor. Subsequently, the alpha chain is added at another site of the Corey acetate derivative yielding 3,3-difluoro-4-phenoxybut-1-enyl-3,5-dihydroxycyclopentyl-hept-5-enoic acid.
- To the 3,3-difluoro-4-phenoxybut-1-enyl-3,5-dihydroxycyclopentyl-hept-5-enoic acid is added iodomethane in a solution of tetrahydroturan (THF) to form 3,3-difluoro-4-phenoxybut-1-enyl-3,5-dihydroxycyclopentyl-methylhept-5-enoate.
- To the 3,3-difluoro-4-phenoxybut-1-enyl-3,5-dihydroxycyclopentyl-methylhept-5-enoate is added ethylamine in water to form 3,3-difluoro-4-phenoxybut-1-enyl-3,5-dihydroxycyclopentyl-N-ethylhept-5-enamide.
-
FIG. 1 shows a process flow from a Corey acetate derivative to the acid, to the ester and then to an ethyl amide (Compound 3). U.S. Pat. No. 5,886,035 also describes a method of preparing difluoro-prostaglandin derivatives but does not describe the use of such derivatives in hair (eyelash) growth. - The following examples provide representative compositions including a difluoro compound such as Compound 3:
-
-
Ingredient Percentage 1. Water (Aqua) 97.791 2. Sodium Chloride 0.877 3. Panthenol 0.020 4. Citric Acid 0.030 5. Phenoxyethanol 0.300 6. Chlorphenesin 0.300 7. Disodium Phosphate 0.142 8. Difluoro Compound 0.024 9. Alcohol 0.216 10. Cellulose Gum 0.300 -
-
Ingredient Percentage 1. USP Water 94.519 2. Sodium Chloride 0.077 3. Phosphoric Acid 0.03 4. Phenoxyethanol 0.3 5. Chlorphenesin 0.3 6. Disodium Phosphate 0.142 7. Cellulose Gum 0.36 8. Biotin 0.5 9. Glycerin 0.6 10. Swertia Japonica Extract 0.045 11. Saw Palmetto Extract 0.064 12. Camellia Sinensis (White Tea) Leaf 0.054 Extract 13. Panax Ginseng 0.075 14. Octapeptide-2 0.93 15. Biotinoyl Tripeptide-1 0.93 16. Wheat Protein 0.25 17. Calendula 0.8 18. Difluoro Compound 0.024 -
-
Ingredient Percentage 1. USP Water 96.031 2. Actiphyte of Rosemary 0.025 3. Phosphoric Acid 0.001 4. Phenoxyethanol 0.3 5. Chlorphenesin 0.3 6. Disodium Phosphate 0.985 7. Cellulose Gum 0.36 8. Biotin 0.24 9. Panthenol 0.25 10. Actiphyte of Nettles 0.1 11. Actiphyte of Horsetail 0.098 12. Actiphyte of Psoralea Seed 0.15 13. Mulberry Root Extract 0.07 14. Actiphyte of Japanese Green Tea 0.25 15. Glycerin 0.6 16. Difluoro Compound (in 10% 0.24 Ethanol Solution) -
-
Ingredient Percentage 1. Water 95.00000 2. Acrylates Copolymer 1.50000 3. Glycerin 1.00000 4. Phenoxyethanol 0.80000 5. Sodium Cocoyl Glutamate 0.35000 6. Chlorphenesin 0.30000 7. Polysorbate 0.25000 8. Trifluoromethyl Dechloro 0.24000 Ethylprostenolamide 9. Disodium EDTA 0.10000 10. Fragrance 0.09610 11. Aminomethyl Propanol 0.09000 12. Panax Ginseng Root Extract 0.08000 13. Panthenol 0.08000 14. Ginko Bilola Leaf Extract 0.05000 15. Biotin 0.05000 16. Serenoa Serrulata Fruit Extract 0.00640 17. Swertia Japonica Extract 0.00450 18. Hydrolyzed Wheat Protein 0.00300 - In another embodiment, compositions for topical application and methods of topical application of a composition to modify hair are described wherein the modification includes increased curl of hair on a subject or hair that is not biologically attached to or is not naturally a part of a subject (e.g., hair of a wig or extension) (“non-natural hair”). In another embodiment, the modification includes increased curl of the hair together with conditioning hair and/or cosmetically improving the appearance or beauty of the hair (e.g., increased look and feel of softness and silkiness). Thus, the compositions described may be applied to existing hair on the scalp or eyelashes or non-natural hair to increase the curl and/or the look and feel of the hair. In one embodiment, a composition includes an effective amount of a compound represented by the following formula:
- wherein the dashed bonds represent a single or double bond and when a bond in either chain is a double bond, cis or trans configuration is contemplated;
- wherein A and B are individually selected from a hydrogen atom, a hydroxyl group (—OH) and a halogen atom (e.g., a fluorine atom), with the proviso that when one of A and B is a hydroxyl group, the other of A and B is a hydrogen atom and when one of A and B is a halogen atom, the other of A and B is a halogen atom or a hydrogen atom;
- wherein Z is a cycloalkyl moiety having from three to seven carbon atoms, an aryl moiety including from four to ten carbon atoms or a heteroaryl moiety including three to nine carbon atoms and at least one heteroatom selected from nitrogen, oxygen and sulfur; and
- wherein X1 and X2 are individually selected from a hydrogen atom, an alkyl moiety having from one to six carbon atoms,
- and
- R5 is an alkyl moiety having from one to six carbon atoms;
- wherein R1 and R2 are individually selected from an oxo group (═O), a hydroxyl group (—OH) or an ester group (—O(CO)R6), and R6 is a saturated or unsaturated acyclic hydrocarbon group having from 1 to about 20 carbon atoms, and —(CH2)mR7 wherein m is 0 or an integer of from 1 to 10, and R7 is cycloalkyl group, having from three to seven carbon atoms, or an aryl or heteroaryl group, as defined above;
- wherein y is 0 or 1, x is 0 or 1 and x and y are not both 1.
- The compound may be in free form (a molecule) or an acceptable salt thereof (a compound) such as a cationic or anionic salt formed at the nitrogen atom of the molecule, in association with a carrier adapted for topical application to mammalian skin. Unless specified, reference to a compound will include a molecule or a compound.
- In one embodiment, the compound is represented by the following formula:
- wherein Y is selected from an alkyl group, a halogen atom (e.g., fluorine, chlorine), a nitro group, an amino group, a thiol group, a hydroxy group, an alkyloxy group, an alkylcarboxy group, a halo substituted alkyl wherein the alkyl includes from one to six carbon atoms, and n is 0 or an integer of from 1 to 3, or an acceptable salt thereof.
- In another embodiment, the compound has the following formula:
- wherein A, B, X1, X2, Y and n are as defined above, or an acceptable salt thereof.
- In a particular embodiment, the compound is selected from any of compounds (1)-(5) above or a molecule having one of the following formulas or a salt thereof:
- Compounds (6)-(9) may be prepared using techniques known in the art including, for example, techniques described in U.S. Pat. Nos. 5,001,153; 5,422,368; 5,510,383; and 5,607,978.
- In one embodiment, the one or more compounds described above (including compounds (1)-(9) is/are mixed with a dermatologically compatible vehicle or carrier. Suitable vehicles include, for example, aqueous solutions such as e.g., physiological salines, oil (e.g., castor oil), water solutions, water/alcohol solutions or ointments. Suitable vehicles furthermore may contain dermatologically compatible preservatives such as e.g., benzalkonium chloride, surfactants like e.g., polysorbate 80, liposomes or polymers, for example, methyl cellulose, polyvinyl alcohol, polyvinyl pyrrolidone and hyaluronic acid; these may be used for increasing the viscosity.
- In one embodiment, dermatological compositions for topical treatment for inducing or stimulating modification of existing hair including increased curl which include an effective hair modifying amount of one or more compounds as defined above and a dermatologically compatible carrier are also disclosed wherein the modification includes increased curl of hair or increased curl. Effective amounts of the compound may be determined by one of ordinary skill in the art but will vary depending on the compound employed, frequency of application and desired result, and the compound will generally range from about 0.0000001 to about 50%, by weight, of the dermatological composition, preferably from about 0.001 to about 50%, by weight, of total dermatological composition, more preferably from about 0.1 to about 30%, by weight of the composition. In another embodiment, a composition may include a combination of compounds described or a compound(s) and other hair treatment aids such as an antioxidant (e.g., Vitamin E), a vasodilator (e.g., minoxidil), an antimicrobial (e.g., benzoyl peroxide), or an anti-inflammatory (e.g., hydrocortisone, cyclooxygenase inhibitor, lipooxigenase inhibitor).
- The composition may be topically applied to existing hair and retained on the hair. Such location may include the scalp or eyelash area of a male or female. Repeated application for a sustained period of time (e.g., daily for several weeks or more (e.g., one month to several months)) may be desired. The composition may be beneficial to persons that naturally have straight scalp hair to aid in the curl of such hair. Evidence of the effectiveness of a composition of compound (3) (dechloro-dihydroxy-difluoro-ethylcloprostenate) and, alternatively, of compound (8) (trifluoromethyl dechloroethyl prostenolamide) in application to generally straight Asian hair indicates a profound curling effect.
- In one embodiment, the composition is suitable for modifying eyelashes. To modify eyelashes, a composition would be provided to a subject with instructions on use (e.g., by instructions on or with a kit, the kit including the composition and the instructions). The subject would be instructed to apply the composition to eyelash hair. In addition to modifying the eyelashes (e.g., increasing the curl and/or look and feel), it is anticipated that application to a hair follicle will increase the thickness (e.g., diameter) of the follicle.
- In one embodiment, the composition may be topically applied to hair on the scalp. For example, a subject interested in establishing a curl to a portion of the subject's scalp hair or improving a natural curl, would be instructed (e.g., by instructions on or with a kit) to topically apply the composition to the desired portion of the hair and to leave the composition on the hair. To improve or sustain the curl over a period of time (e.g., days, weeks), the subject would be instructed to repeat the application for a period ranging from days to weeks.
- In another embodiment, the applications described above may be used to modify non-natural hair (e.g., hair not biologically attached to or is not naturally a part of a subject). Examples of such hair include, but are not limited to, wigs and hair extensions.
- In another embodiment, a kit is disclosed. The kit may include the composition of at least one compound having the formula III or IV as described above in a dermatologically compatible vehicle or carrier in a container. The container includes an amount of the composition for repeated application over a period, such as enough of the composition for daily application over a period of six months. The container may also include an applicator, such as a mascara brush or other instrument for application of the composition to skin. In the case of a composition in the form of a foam, the container may be pressurized and include a nozzle to dispense a desired amount onto the hand of a user.
- The following example used trifluoromethyl dechloroethyl prostenolamide (TDP) as a compound. TDP has the following formula:
- A solution of TDP was prepared including 97.6 percent water, 0.24 percent TDP and 2.16 percent ethyl alcohol. Samples of human hair separated from a subject were treated with water alone while others were treated with the TDP solution. The treatment involved dipping the dry hair samples into the water and TDP solutions to one minute. Unexpectedly, there appeared a definite increase in curl in each of the hair samples when treated with the TDP solution. The hair treated with water alone did not show similar curl. The results are illustrated in
FIG. 1 . In addition, the hair treated with the TDP solution had a noticeable and palpable increase in the look and feel of softness and silkiness compared to the hair treated with the water alone. - In the preceding detailed description, reference is made to specific embodiments thereof. It will, however, be evident that various modifications and changes may be made thereto without departing from the broader spirit and scope of the following claims. The specification and drawings are, accordingly, to be regarded in an illustrative rather than a restrictive sense.
Claims (19)
1. A composition comprising a compound of the formula:
wherein the dashed bonds represent a single or double bond; R and R′ are individually selected from the group consisting of hydrogen, a C1-C6 straight or branched chain alkyl; X is selected from the group consisting of a halide, a halide containing group or a hydrogen; y is 0 or 1, x is 0 or 1 and x and y are not both 1 or not both 0; or a salt thereof.
7. The composition of claim 1 , further comprising a dermatologically acceptable carrier.
8. A method comprising:
directly applying to dermis or hair on the dermis an amount of a composition comprising a compound of the formula:
wherein the dashed bonds represent a single or double bond, R and R′ are individually selected from the group consisting of hydrogen, a C1-C6 straight or branched chain alkyl, X is selected from the group consisting of a halide, a halide containing group or a hydrogen, y is 0 or 1, x is 0 or 1 and x and y are not both 1, or a salt thereof.
9. The method of claim 7 , wherein the dermis includes an eyelid.
14. The method of claim 8 , wherein the composition further comprises a dermatologically acceptable carrier.
15. A kit comprising:
a container;
a composition comprising a compound of the formula:
wherein the dashed bonds represent a single or double bond; R and R′ are individually selected from the group consisting of hydrogen, a C1-C6 straight or branched chain alkyl; X is selected from the group consisting of a halide, a halide containing group or a hydrogen; y is 0 or 1, x is 0 or 1 and x and y are not both 1 or not both 0; or a pharmaceutically acceptable salt thereof, and
wherein the container includes an amount of the composition for repeated application over a period.
16. The kit of claim 15 further comprising an applicator.
18. A method comprising:
directly applying to hair an effective amount of a composition to effect a curl of the hair, the composition comprising a compound of the formula:
wherein the dashed bonds represent a single or double bond;
wherein A and B are individually selected from a hydrogen atom, a hydroxyl group (—OH) and a halogen atom (e.g., a fluorine atom), with the proviso that when one of A and B is a hydroxyl group, the other of A and B is a hydrogen atom and when one of A and B is a halogen atom, the other of A and B is a halogen atom or a hydrogen atom;
wherein Z is a cycloalkyl moiety having from three to seven carbon atoms, an aryl moiety including from four to ten carbon atoms or a heteroaryl moiety including three to nine carbon atoms and at least one heteroatom selected from nitrogen, oxygen and sulfur; and
wherein X1 and X2 are individually selected from a hydrogen atom, an alkyl moiety having from one to six carbon atoms,
and
R5 is an alkyl moiety having from one to six carbon atoms;
wherein R1 and R2 are individually selected from an oxo group, a hydroxyl group or an ester group, and R6 is a saturated or unsaturated acyclic hydrocarbon group having from 1 to about 20 carbon atoms, and —(CH2)mR7 wherein m is 0 or an integer of from 1 to 10, and R7 is cycloalkyl group, having from three to seven carbon atoms, or an aryl or heteroaryl group, as defined above; and
wherein y is 0 or 1, x is 0 or 1 and x and y are not both 1, or a salt thereof.
19. The method of claim 18 , wherein the hair comprises eyelashes.
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12/698,823 US20110293549A1 (en) | 2009-02-03 | 2010-02-02 | Composition, method and kit for enhancing hair |
| US13/631,193 US9006291B2 (en) | 2009-02-03 | 2012-09-28 | Composition, method and kit for enhancing hair |
| US14/661,962 US20150190322A1 (en) | 2009-02-03 | 2015-03-18 | Composition, method and kit for enhancing hair |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14966109P | 2009-02-03 | 2009-02-03 | |
| US12/698,823 US20110293549A1 (en) | 2009-02-03 | 2010-02-02 | Composition, method and kit for enhancing hair |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US13/631,193 Continuation US9006291B2 (en) | 2009-02-03 | 2012-09-28 | Composition, method and kit for enhancing hair |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| US20110293549A1 true US20110293549A1 (en) | 2011-12-01 |
Family
ID=45022312
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US12/698,823 Abandoned US20110293549A1 (en) | 2009-02-03 | 2010-02-02 | Composition, method and kit for enhancing hair |
| US13/631,193 Active US9006291B2 (en) | 2009-02-03 | 2012-09-28 | Composition, method and kit for enhancing hair |
| US14/661,962 Abandoned US20150190322A1 (en) | 2009-02-03 | 2015-03-18 | Composition, method and kit for enhancing hair |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US13/631,193 Active US9006291B2 (en) | 2009-02-03 | 2012-09-28 | Composition, method and kit for enhancing hair |
| US14/661,962 Abandoned US20150190322A1 (en) | 2009-02-03 | 2015-03-18 | Composition, method and kit for enhancing hair |
Country Status (1)
| Country | Link |
|---|---|
| US (3) | US20110293549A1 (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110293549A1 (en) * | 2009-02-03 | 2011-12-01 | Athena Cosmetics, Inc. | Composition, method and kit for enhancing hair |
| US11744788B2 (en) * | 2021-10-27 | 2023-09-05 | James D. Welch | Method of encouraging growth and regrowth of hair in human males technical area |
| FR3152224A1 (en) * | 2023-08-22 | 2025-02-28 | Doll Up Secret - Fzco | Cosmetic composition intended for the treatment of eyelashes and eyebrows |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030147823A1 (en) * | 2002-02-04 | 2003-08-07 | Allergan, Inc. | Method of enhancing hair growth |
Family Cites Families (134)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3461461A (en) | 1965-11-01 | 1969-08-12 | Upjohn Co | 6-amino-4-(substituted amino)-1,2-dihydro-1-hydroxy-2-iminopyrimidines |
| BE755555A (en) | 1969-09-02 | 1971-03-01 | Richardson Merrell Inc | QUINOXALINE DERIVATIVES |
| US4304907A (en) | 1972-05-10 | 1981-12-08 | The Upjohn Company | Bicyclo lactone intermediates for prostaglandin analogs |
| US3922297A (en) | 1973-01-16 | 1975-11-25 | Upjohn Co | Prostaglandin E{HD 1{B , F{HD 1{B , and A{HD 1 {B analogs |
| FR2400895A1 (en) | 1974-01-31 | 1979-03-23 | Aries Robert | 10-Fluoro or 12-fluoro-prostaglandin derivs. - and lactone precursors, useful in human or veterinary medicine |
| US3931282A (en) | 1974-02-21 | 1976-01-06 | Syntex (U.S.A.) Inc. | 11α-Hydroxymethyl prostaglandins |
| US4217360A (en) | 1975-02-27 | 1980-08-12 | Schering Aktiengesellschaft | Novel 1,3-benzodioxaneprostanoic acid derivatives and process for the preparation thereof |
| DE2517771A1 (en) | 1975-04-18 | 1976-10-28 | Schering Ag | NEW PROSTAGLANDIN ACETYLENE ANALOGS AND METHOD FOR THEIR PRODUCTION |
| ES449162A1 (en) | 1975-06-23 | 1977-12-16 | Syntex Inc | 16-Phenoxy and 16-substituted phenoxy-prostatrienoic acid derivatives |
| US4005133A (en) | 1975-10-14 | 1977-01-25 | The Upjohn Company | PGF2.sub.α, L-Arginine salt |
| US4139619A (en) | 1976-05-24 | 1979-02-13 | The Upjohn Company | 6-Amino-4-(substituted amino)-1,2-dihydro-1-hydroxy-2-iminopyrimidine, topical compositions and process for hair growth |
| US4178457A (en) | 1978-07-10 | 1979-12-11 | Syntex (U.S.A.) Inc. | (dl)-16-Phenoxy- and 16-substituted phenoxy-9-keto prostatrienoic acid derivatives and processes for the production thereof |
| JPS6032718Y2 (en) | 1981-06-10 | 1985-09-30 | 松下電工株式会社 | Alarm input control circuit using integrated circuit for speech synthesis |
| US4599353A (en) | 1982-05-03 | 1986-07-08 | The Trustees Of Columbia University In The City Of New York | Use of eicosanoids and their derivatives for treatment of ocular hypertension and glaucoma |
| JPS59227888A (en) | 1983-06-10 | 1984-12-21 | Asahi Glass Co Ltd | Production of 7-fluoroprostaglandin |
| US4912235A (en) | 1983-12-22 | 1990-03-27 | Syntex (U.S.A.) Inc. | Processes and intermediates for making 16-phenoxy- and 16-substituted phenoxy-prostatrienoic acid derivatives and their stereoisomers |
| JPS6134778U (en) | 1984-07-31 | 1986-03-03 | 株式会社明電舎 | electrical equipment storage box |
| JPS61218510A (en) | 1985-03-22 | 1986-09-29 | Dai Ichi Seiyaku Co Ltd | Agent for hair |
| US4889845A (en) | 1986-06-09 | 1989-12-26 | American Cyanamid Company | Vehicle for topical application of pharmaceuticals |
| ATE108330T1 (en) | 1987-09-18 | 1994-07-15 | R Tech Ueno Ltd | HYPOTENSIVE OCULAR MEDIUM. |
| US5296504A (en) | 1988-09-06 | 1994-03-22 | Kabi Pharmacia | Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension |
| US6187813B1 (en) | 1990-04-10 | 2001-02-13 | Pharmacia & Upjohn Aktiebolag | Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension |
| US5321128A (en) | 1988-09-06 | 1994-06-14 | Kabi Pharmacia Ab | Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension |
| ATE420857T1 (en) | 1988-09-06 | 2009-01-15 | Pfizer Health Ab | PROSTAGLANDIN DERIVATIVES FOR THE TREATMENT OF GLAUCOMA AND OCULAR HYPERTENSION |
| US4968812A (en) | 1989-06-23 | 1990-11-06 | Shell Oil Company | Spirolactonelactams |
| SE9002596D0 (en) | 1990-08-08 | 1990-08-08 | Pharmacia Ab | A METHOD OF SYNTHESIS OF PROSTAGLANDIN DERIVATIVES |
| US5288754A (en) | 1992-02-04 | 1994-02-22 | Allergan, Inc. | Polar C-1 esters of prostaglandins |
| JP3102141B2 (en) | 1992-05-29 | 2000-10-23 | 東レ株式会社 | Hair restorer |
| US5972991A (en) | 1992-09-21 | 1999-10-26 | Allergan | Cyclopentane heptan(ene) oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents |
| US5688819A (en) | 1992-09-21 | 1997-11-18 | Allergan | Cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents |
| US5352708A (en) | 1992-09-21 | 1994-10-04 | Allergan, Inc. | Non-acidic cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents |
| US5834498A (en) | 1992-09-21 | 1998-11-10 | Allergan | Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents |
| US6602900B2 (en) | 1992-09-21 | 2003-08-05 | Allergan, Inc. | Cyclopentane heptan(ENE)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents |
| JP3083925B2 (en) | 1992-11-24 | 2000-09-04 | ティーディーケイ株式会社 | Electronic component mounting method and device |
| US6184250B1 (en) | 1993-08-03 | 2001-02-06 | Alcon Laboratories, Inc. | Use of cloprostenol and fluprostenol analogues to treat glaucoma and ocular hypertension |
| US5510383A (en) | 1993-08-03 | 1996-04-23 | Alcon Laboratories, Inc. | Use of cloprostenol, fluprostenol and their salts and esters to treat glaucoma and ocular hypertension |
| US5387608A (en) | 1993-08-17 | 1995-02-07 | Allergan, Inc. | Cyclopentane(ene) heptanoic or cyclopentane(ene) heptenoic acid, 2-hydrocarbyl sulfonamidomethyl and derivatives thereof as therapeutic agents |
| US6323204B1 (en) | 1993-10-13 | 2001-11-27 | Allergan | Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives |
| SE9303444D0 (en) | 1993-10-20 | 1993-10-20 | Kabi Pharmacia Ab | New use of prostaglandins |
| US5545665A (en) | 1993-12-28 | 1996-08-13 | Allergan | Cyclopentane(ene) heptenoic or heptanoic acids and derivatives thereof useful as therapeutic agents |
| US6124344A (en) | 1993-12-28 | 2000-09-26 | Allergan Sales, Inc. | Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents |
| US5516796A (en) | 1994-03-24 | 1996-05-14 | Kabi Pharmacia Ab | Thioprostaglandins and -prostaglandin-like compounds and therapeutic uses thereof |
| US5631287A (en) | 1994-12-22 | 1997-05-20 | Alcon Laboratories, Inc. | Storage-stable prostaglandin compositions |
| US6011062A (en) | 1994-12-22 | 2000-01-04 | Alcon Laboratories, Inc. | Storage-stable prostaglandin compositions |
| US6441047B2 (en) | 1995-11-17 | 2002-08-27 | Alcon Manufacturing Ltd.. | Combination therapy for treating glaucoma |
| US5741810A (en) | 1996-02-29 | 1998-04-21 | Allergan | Cyclopentane heptan(ene)oic acid, 2- heteroarylalkenyl derivatives as therapeutic agents |
| US6440460B1 (en) | 1996-03-05 | 2002-08-27 | Allergan Sales, Inc. | Pharmaceutical compositions containing buffered ortho ester polymers |
| JP2000511530A (en) | 1996-05-28 | 2000-09-05 | アラーガン・セイルズ・インコーポレイテッド | Cyclopentanoic (ene) acid, 2-alkenyl derivative as medicament for ocular hypertension treatment |
| DK0857718T3 (en) | 1996-06-10 | 2002-12-16 | Sucampo Ag | endothelin antagonist |
| JPH1087607A (en) | 1996-09-17 | 1998-04-07 | Asahi Glass Co Ltd | Method for producing fluorine-containing prostaglandin derivative |
| WO1998012175A1 (en) | 1996-09-17 | 1998-03-26 | Asahi Glass Company Ltd. | Fluorinated prostaglandin derivatives and medicines |
| JP3480549B2 (en) | 1996-12-26 | 2003-12-22 | 参天製薬株式会社 | Difluoroprostaglandin derivatives and uses thereof |
| AU750039B2 (en) | 1997-02-04 | 2002-07-11 | Murray A. Johnstone | Method of enhancing hair growth |
| CN1224354A (en) | 1997-02-27 | 1999-07-28 | 东丽株式会社 | pulmonary circulation improver |
| JP3217293B2 (en) | 1997-04-17 | 2001-10-09 | 株式会社アールテック・ウエノ | Hair growth / hair restorer |
| WO1999012899A1 (en) | 1997-09-09 | 1999-03-18 | The Procter & Gamble Company | A process for making prostaglandin f analogs |
| KR20010023837A (en) | 1997-09-09 | 2001-03-26 | 데이비드 엠 모이어 | Aromatic c16-c20-substituted tetrahydro prostaglandins useful as fp agonists |
| EP1012137B1 (en) | 1997-09-09 | 2002-11-06 | The Procter & Gamble Company | Aromatic c16-c20-substituted tetrahydro prostaglandins useful as fp agonists |
| ID23971A (en) | 1997-09-09 | 2000-06-14 | Procter & Gamble | PROSTAGLANDIN TETRAHIDRO SUBSTITUTEDIC C <16> -C <20> AROMATICS USING AS FP AGONISTS |
| US6066671A (en) | 1997-12-19 | 2000-05-23 | Alcon Laboratories, Inc. | Treatment of GLC1A glaucoma with 3-benzoyl-phenylacetic acids, esters, or amides |
| US6646001B2 (en) | 1997-12-19 | 2003-11-11 | Alcon Manufacturing, Ltd. | Use of non-steroidal anti-inflammatory agents in combination with prostaglandin FP receptor agonists to treat glaucoma and ocular hypertension |
| AU749540B2 (en) | 1998-03-31 | 2002-06-27 | Duke University | C11oxymyl and hydroxylamino prostaglandins useful as FP agonists |
| KR20010042286A (en) | 1998-03-31 | 2001-05-25 | 데이비드 엠 모이어 | C11 oxymyl and hydroxylamino prostaglandins useful as medicaments |
| US6444840B1 (en) | 1998-03-31 | 2002-09-03 | The Procter & Gamble Co. | C11 oxymyl and hydroxylamino prostaglandins useful as FP agonists |
| US6235781B1 (en) | 1998-07-14 | 2001-05-22 | Alcon Laboratories, Inc. | Prostaglandin product |
| US6284234B1 (en) | 1998-08-04 | 2001-09-04 | Johnson & Johnson Consumer Companies, Inc. | Topical delivery systems for active agents |
| WO2000018316A2 (en) | 1998-09-25 | 2000-04-06 | Alcon Laboratories, Inc. | Sustained release, and comfortable ophthalmic composition and method for ocular therapy |
| CZ20013174A3 (en) | 1999-03-05 | 2002-02-13 | The Procter & Gamble Company | C 16 unsaturated FP-selective prostaglandin analogs |
| IL145123A0 (en) | 1999-03-05 | 2002-06-30 | Procter & Gamble | C16 unsaturated fp-selective prostaglandin analogs |
| EP1202999B1 (en) | 1999-08-04 | 2003-06-18 | The Procter & Gamble Company | Novel 2-decarboxy-2-phosphinico prostaglandin f analogs |
| US6894175B1 (en) | 1999-08-04 | 2005-05-17 | The Procter & Gamble Company | 2-Decarboxy-2-phosphinico prostaglandin derivatives and methods for their preparation and use |
| US20020172693A1 (en) | 2000-03-31 | 2002-11-21 | Delong Michell Anthony | Compositions and methods for treating hair loss using non-naturally occurring prostaglandins |
| US20020013294A1 (en) | 2000-03-31 | 2002-01-31 | Delong Mitchell Anthony | Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives |
| US20020146439A1 (en) | 2000-03-31 | 2002-10-10 | Delong Mitchell Anthony | Compositions and methods for treating hair loss using oximyl and hydroxylamino prostaglandins |
| US20020037914A1 (en) | 2000-03-31 | 2002-03-28 | Delong Mitchell Anthony | Compositions and methods for treating hair loss using C16-C20 aromatic tetrahydro prostaglandins |
| CA2402405C (en) | 2000-07-14 | 2008-02-12 | Allergan Sales, Inc. | Compositions containing alpha-2-adrenergic agonist components |
| FR2812191B1 (en) | 2000-07-28 | 2003-10-17 | Oreal | USE OF PROSTAGLANDIN E2 RECEPTOR AGONISTS (EP-3) TO ATTENUATE, DECREASE OR STOP HAIR AND HAIR GROWTH IN COSMETIC PREPARATIONS |
| FR2812193B1 (en) | 2000-07-28 | 2003-10-24 | Oreal | USE OF AN ANTAGONIST OF PROSTAGLANDIN EP-2 AND / OR EP-4 RECEPTORS TO ATTENUATE, DECREASE OR STOP HAIR AND HAIR GROWTH IN COSMETIC PREPARATIONS |
| US6407250B1 (en) | 2000-09-14 | 2002-06-18 | Allergan Sales, Inc. | Interphenylene 7-oxabicyclic [2.2.1] heptane oxazoles as prostaglandin F2a antagonists |
| US6511999B2 (en) | 2000-09-14 | 2003-01-28 | Allergan, Inc. | Interheteroaryl 7-oxabicyclic [2.2.1]heptane oxazoles as prostaglandin F2α antagonists |
| US6369089B1 (en) | 2000-09-14 | 2002-04-09 | Allergan Sales, Inc. | Interheteroaryl 7-oxabicyclic [2.2.1]heptane oxazoles as prostaglandin F2α antagonists |
| US6248783B1 (en) | 2000-09-20 | 2001-06-19 | Allergan Sales, Inc. | Cyclopentane 1-hydroxy alkyl or alkenyl-2-one or 2-hydroxy derivatives as therapeutic agents |
| US6291522B1 (en) | 2000-09-27 | 2001-09-18 | Allergan Sales, Inc. | Cyclopentane heptan(ENE)oic acid, 2-thiocarbamoyloxy and 2-carbamoyloxy compounds as therapeutic agents |
| US7060297B2 (en) | 2000-11-06 | 2006-06-13 | Alcon, Inc. | Carrageenan viscoelastics for ocular surgery |
| US6787517B1 (en) | 2000-12-29 | 2004-09-07 | Allergan, Inc. | Agent and methods for treating pain |
| PL202778B1 (en) | 2001-02-22 | 2009-07-31 | Skyepharma Canada Inc | Fibrate-statin combinations with reduced fed-fasted effects |
| US6410591B1 (en) | 2001-05-08 | 2002-06-25 | Allergan Sales, Inc. | 3,7 or 3 and 7 thia or oxa prostanoic acid derivatives as agents for lowering intraocular pressure |
| US6531504B2 (en) | 2001-05-17 | 2003-03-11 | Allergan, Inc. | Prostanoic acid derivatives as agents for lowering intraocular pressure |
| US6476064B1 (en) | 2001-06-13 | 2002-11-05 | Allergan, Inc. | Cyclopentane heptan(ene) acyl sulfonamide, 2-alkyl or 2-arylalkyl, or 2-heteroarylalkenyl derivatives as therapeutic agents |
| US20030027853A1 (en) | 2001-06-14 | 2003-02-06 | Allergan Sales, Inc. | 3, 7or3 and 7 thia or oxa prostanoic acid derivatives as agents for lowering intraocular pressure |
| US6713268B2 (en) | 2001-06-26 | 2004-03-30 | Allergan, Inc. | Methods of identifying ocular hypotensive compounds having reduced hyperpigmentation |
| US6743439B1 (en) | 2001-06-27 | 2004-06-01 | Alcon, Inc. | Ophthalmic compositions containing copolymers of sulfonated styrene and maleic anhydride |
| EP1298223A3 (en) | 2001-09-28 | 2003-07-23 | Pfizer Products Inc. | Methods related to the A-C repeat Z-sequence upstream from the aldose reductase gene |
| CN1617868A (en) | 2001-11-05 | 2005-05-18 | 阿勒根公司 | Omega-cycloalkyl 17-heteroaryl prostaglandin E2 analogs as EP2-receptor agonists |
| SE0104334D0 (en) | 2001-12-19 | 2001-12-19 | Astrazeneca Ab | Therapeutic agents |
| US20040082013A1 (en) | 2002-01-24 | 2004-04-29 | Regan John W | Methods for screening for substances which inhibit fp prostanoid receptor interaction with a compound having pgf2alpha activity and methods of treating cancer |
| ATE336247T1 (en) | 2002-03-18 | 2006-09-15 | Pfizer Prod Inc | USE OF SELECTIVE EP4 RECEPTOR AGONISTS TO TREAT DISEASES |
| GB0208785D0 (en) | 2002-04-17 | 2002-05-29 | Medical Res Council | Treatment methtods |
| JP2003321442A (en) | 2002-04-24 | 2003-11-11 | Santen Pharmaceut Co Ltd | Novel difluoroprostaglandin amide derivatives |
| US6573294B1 (en) | 2002-05-14 | 2003-06-03 | Allergan, Inc. | 8-azaprostaglandin analogs as agents for lowering intraocular pressure |
| US7521530B2 (en) | 2002-06-11 | 2009-04-21 | Universite De Montreal | Peptides and peptidomimetics useful for inhibiting the activity of prostaglandin F2α receptor |
| US20030199590A1 (en) | 2002-07-25 | 2003-10-23 | Cagle Gerald D | Prostaglandin analogues for promotion of hair growth |
| US6864282B2 (en) | 2002-08-05 | 2005-03-08 | Allergan, Inc. | 9,11-cycloendoperoxide pro-drugs of prostaglandin analogues for treatment of ocular hypertension and glaucoma |
| JP2006501245A (en) | 2002-08-30 | 2006-01-12 | アルコン,インコーポレイテッド | Substituted 5-chroman-5-yl-ethylamine compounds and their use for the treatment of glaucoma |
| US6875787B2 (en) | 2003-02-11 | 2005-04-05 | Allergan, Inc. | 10,10-dialkyl prostanoic acid derivatives as agents for lowering intraocular pressure |
| US6734206B1 (en) | 2003-06-02 | 2004-05-11 | Allergan, Inc. | 3-oxa-8-azaprostaglandin analogs as agents for lowering intraocular pressure |
| KR20110134525A (en) | 2003-06-13 | 2011-12-14 | 알콘, 인코퍼레이티드 | Ophthalmic composition comprising two synergistic polymer blends |
| TWI336257B (en) | 2003-06-13 | 2011-01-21 | Alcon Inc | Ophthalmic compositions containing a synergistic combination of three polymers |
| US7589233B2 (en) | 2003-07-29 | 2009-09-15 | Signature R&D Holdings, Llc | L-Threonine derivatives of high therapeutic index |
| US7015243B2 (en) | 2003-08-28 | 2006-03-21 | Allergan, Inc. | Cyclohexyl prostaglandin analogs as EP4-receptor agonists |
| US7045634B2 (en) | 2003-09-05 | 2006-05-16 | Allergan, Inc. | Prostamide receptor antagonists |
| US20050058614A1 (en) | 2003-09-15 | 2005-03-17 | Allergan, Inc. | Methods for the treatment of gray hair using cyclopentane(ene) heptan(en)oic acid amides |
| US7070768B2 (en) | 2003-09-25 | 2006-07-04 | Allergan, Inc. | Method for imparting artificial tan to human skin |
| US7186744B2 (en) | 2003-11-13 | 2007-03-06 | Allergan, Inc. | Prostamides for the treatment of glaucoma and related diseases |
| US20050112075A1 (en) | 2003-11-25 | 2005-05-26 | Hwang Cheng S. | Reduction of hair growth |
| US7129257B1 (en) | 2003-12-15 | 2006-10-31 | Alcon, Inc. | Pyrazolo[3,4- e]benzoxazoles for the treatment of glaucoma |
| WO2005058911A2 (en) | 2003-12-15 | 2005-06-30 | Alcon, Inc. | Substituted [1,4]oxazino[2,3-g]indazoles for the treatment of glaucoma |
| AU2005237543B2 (en) | 2004-04-26 | 2011-02-10 | Alcon, Inc. | Statins for the treatment of ocular hypertension and glaucoma |
| US20060182781A1 (en) | 2004-04-30 | 2006-08-17 | Allergan, Inc. | Methods for treating ocular conditions with cyclic lipid contraining microparticles |
| US7183310B2 (en) | 2004-08-10 | 2007-02-27 | Allergan, Inc. | Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents |
| US7101904B2 (en) | 2004-08-10 | 2006-09-05 | Allergan, Inc. | Cyclopentane heptan(ENE)OIC acid, 2-heteroarylalkenyl derivatives as therapeutic agents |
| US7101906B2 (en) | 2004-11-16 | 2006-09-05 | Allergan, Inc. | 2,3,4-substituted cyclopentanones as therapeutic agents |
| US7183324B2 (en) | 2004-11-23 | 2007-02-27 | Allergan, Inc. | 2,3,4-substituted cyclopentanones as therapeutic agents |
| US7091231B2 (en) | 2004-12-10 | 2006-08-15 | Allergan, Inc. | 12-Aryl prostaglandin analogs |
| US20060154981A1 (en) | 2005-01-12 | 2006-07-13 | Alcon, Inc. | Method of reducing intraocular pressure and treating glaucoma |
| GB0506759D0 (en) | 2005-04-02 | 2005-05-11 | Medical Res Council | Combination treatment methods |
| CA2613010A1 (en) | 2005-06-29 | 2007-01-04 | Pfizer Inc. | Fluoroprostaglandins nitroderivatives |
| US7879910B1 (en) | 2006-10-10 | 2011-02-01 | Jan Marini Skin Research, Inc. | Compositions and methods for promoting lush hair growth |
| US7868032B2 (en) | 2006-10-18 | 2011-01-11 | Allergan, Inc. | Prostamide receptor antagonists |
| CN102143753B (en) | 2008-09-04 | 2013-07-03 | 参天制药株式会社 | Hair growth promoter containing 15,15-difluoroprostaglandin F2α derivative as an active ingredient |
| WO2010096123A2 (en) | 2008-10-29 | 2010-08-26 | Aerie Pharmaceuticals, Inc. | Amino acid salts of prostaglandins |
| US20110293549A1 (en) * | 2009-02-03 | 2011-12-01 | Athena Cosmetics, Inc. | Composition, method and kit for enhancing hair |
| WO2010108012A1 (en) | 2009-03-18 | 2010-09-23 | Duke University | Compositions and methods for promoting nasal patency and treating neurogenic bladder using prostaglandins |
| JP5331025B2 (en) | 2010-02-18 | 2013-10-30 | 八千代工業株式会社 | Sunroof device guide pipe holding structure |
-
2010
- 2010-02-02 US US12/698,823 patent/US20110293549A1/en not_active Abandoned
-
2012
- 2012-09-28 US US13/631,193 patent/US9006291B2/en active Active
-
2015
- 2015-03-18 US US14/661,962 patent/US20150190322A1/en not_active Abandoned
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030147823A1 (en) * | 2002-02-04 | 2003-08-07 | Allergan, Inc. | Method of enhancing hair growth |
Non-Patent Citations (1)
| Title |
|---|
| Jean-Pierre Begue & Daniele Bonnet-Delpon, Recent Advances (1995-2005) in Fluorinated Pharmaceutical Based on Natural Products, 127 J FLUOR. CHEM. 992 (2006) * |
Also Published As
| Publication number | Publication date |
|---|---|
| US20150190322A1 (en) | 2015-07-09 |
| US9006291B2 (en) | 2015-04-14 |
| US20130046024A1 (en) | 2013-02-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20090018204A1 (en) | Composition and method for enhancing hair growth | |
| AU2003207843B2 (en) | Method of enhancing hair growth | |
| EP3062797B1 (en) | Compositions for reducing hair loss and/or increasing hair regrowth | |
| US20110112198A1 (en) | Compositions for enhancing hair growth | |
| US9006291B2 (en) | Composition, method and kit for enhancing hair | |
| US8859616B2 (en) | Compounds and methods for enhancing hair growth | |
| EP2600825B1 (en) | Method for curling hair | |
| US20100305047A1 (en) | Cyclosporin derivatives for enhancing the growth of hair | |
| JP6188837B2 (en) | Non-therapeutic hair curl method | |
| HK1181669B (en) | Composition, method and kit for enhancing hair | |
| HK1181669A (en) | Composition, method and kit for enhancing hair | |
| AU2012261499B2 (en) | Method of enhancing hair growth | |
| AU2012207093A1 (en) | Compounds and methods for enhancing hair growth |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AS | Assignment |
Owner name: ATHENA COSMETICS, INC., NEVADA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:BRINKENHOFF, MICHAEL C.;REEL/FRAME:023887/0624 Effective date: 20100202 |
|
| AS | Assignment |
Owner name: PHARMA PATENT HOLDING INC., CALIFORNIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:ATHENA COSMETICS, INC.;REEL/FRAME:029044/0231 Effective date: 20120808 |
|
| STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |